@article{ScheerWilson2016,
  author    = {Scheer, Nico and Wilson, Ian D.},
  title     = {A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity},
  series = {Drug Discovery Today},
  volume    = {21},
  journal   = {Drug Discovery Today},
  number    = {2},
  publisher = {Elsevier},
  address   = {Amsterdam},
  issn      = {1359-6446},
  doi       = {10.1016/j.drudis.2015.09.002},
  pages     = {250 -- 263},
  year      = {2016},
  abstract  = {Mice that have been genetically humanized for proteins involved in drug metabolism and toxicity and mice engrafted with human hepatocytes are emerging and promising in vivo models for an improved prediction of the pharmacokinetic, drug-drug interaction and safety characteristics of compounds in humans. The specific advantages and disadvantages of these models should be carefully considered when using them for studies in drug discovery and development. Here, an overview on the corresponding genetically humanized and chimeric liver humanized mouse models described to date is provided and illustrated with examples of their utility in drug metabolism and toxicity studies. We compare the strength and weaknesses of the two different approaches, give guidance for the selection of the appropriate model for various applications and discuss future trends and perspectives.},
  language  = {en}
}
@article{ScheerRossRodeetal.2008,
  author    = {Scheer, Nico and Ross, Jillian and Rode, Anja and Zevnik, Branko and Niehaves, Sandra and Faust, Nicole and Wolf, C. Roland},
  title     = {A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response},
  series = {Journal of Clinical Investigation},
  volume    = {118},
  journal   = {Journal of Clinical Investigation},
  number    = {9},
  issn      = {1558-8238},
  doi       = {https://doi.org/10.1172/JCI35483},
  pages     = {3228 -- 3239},
  year      = {2008},
  language  = {en}
}
@article{ScheerRiedlWarrenetal.2002,
  author    = {Scheer, Nico and Riedl, Iris and Warren, J.T. and Kuwada, John Y. and Campos-Ortega, Jos{\´e} A.},
  title     = {A quantitative analysis of the kinetics of Gal4 activator and effector gene expression in the zebrafish},
  series = {Mechanism of Development},
  volume    = {112},
  journal   = {Mechanism of Development},
  number    = {1-2},
  issn      = {0925-4773},
  doi       = {10.1016/S0925-4773(01)00621-9},
  pages     = {9 -- 14},
  year      = {2002},
  language  = {en}
}
@article{HendersonScheerWolf2009,
  author    = {Henderson, Colin J. and Scheer, Nico and Wolf, C. Roland},
  title     = {Advances in the generation of mouse models to elucidate the pathways of drug metabolism in rodents and man},
  series = {Expert Review of Clinical Pharmacology},
  volume    = {2},
  journal   = {Expert Review of Clinical Pharmacology},
  number    = {2},
  publisher = {Taylor \& Francis},
  address   = {London},
  issn      = {1751-2441},
  doi       = {10.1586/17512433.2.2.105},
  pages     = {105 -- 109},
  year      = {2009},
  language  = {en}
}
@article{ScheerHendersonKapelyukhetal.2019,
  author    = {Scheer, Nico and Henderson, Colin James and Kapelyukh, Yury and Rode, Anja and Mclaren, Aileen W. and MacLeod, Alastair Kenneth and Lin, De and Wright, Jayne and Stanley, Lesley and Wolf, C. Roland},
  title     = {An extensively humanised mouse model to predict pathways of drug disposition, drug/drug interactions, and to facilitate the design of clinical trials},
  series = {Drug Metabolism and Disposition},
  journal   = {Drug Metabolism and Disposition},
  number    = {Early view},
  doi       = {10.1124/dmd.119.086397},
  pages     = {69 Seiten},
  year      = {2019},
  language  = {en}
}
@article{ScheerGrothHansetal.2001,
  author    = {Scheer, Nico and Groth, Anne and Hans, Stefan and Campos-Ortega, Jos{\´e} A.},
  title     = {An instructive function for Notch in promoting gliogenesis in the zebrafish retina},
  series = {Development},
  volume    = {128},
  journal   = {Development},
  number    = {7},
  issn      = {0950-1991},
  pages     = {1099 -- 1107},
  year      = {2001},
  language  = {en}
}
@article{ReugelsBoggettiScheeretal.2006,
  author    = {Reugels, Alexander M. and Boggetti, Barbara and Scheer, Nico and Campos-Ortega, Jos{\´e} A.},
  title     = {Asymmetric localization of Numb:EGFP in dividing neuroepithelial cells during neurulation in Danio rerio},
  series = {Developmental Dynamics},
  volume    = {235},
  journal   = {Developmental Dynamics},
  number    = {4},
  issn      = {1097-0177},
  doi       = {10.1002/dvdy.20699},
  pages     = {934 -- 948},
  year      = {2006},
  language  = {en}
}
@article{ZhangHeimbachScheeretal.2016,
  author    = {Zhang, Jin and Heimbach, Tycho and Scheer, Nico and Barve, Avantika and Li, Wenkui and Lin, Wen and He, Handan},
  title     = {Clinical Exposure Boost Predictions by Integrating Cytochrome P450 3A4-Humanized Mouse Studies With PBPK Modeling},
  series = {Journal of Pharmaceutical Sciences},
  volume    = {Volume 105},
  journal   = {Journal of Pharmaceutical Sciences},
  number    = {Issue 4},
  publisher = {Elsevier},
  address   = {Amsterdam},
  issn      = {0022-3549},
  doi       = {doi.org/10.1016/j.xphs.2016.01.021},
  pages     = {1398 -- 1404},
  year      = {2016},
  abstract  = {NVS123 is a poorly water-soluble protease 56 inhibitor in clinical development. Data from in vitro hepatocyte studies suggested that NVS123 is mainly metabolized by CYP3A4. As a consequence of limited solubility, NVS123 therapeutic plasma exposures could not be achieved even with high doses and optimized formulations. One approach to overcome NVS123 developability issues was to increase plasma exposure by coadministrating it with an inhibitor of CYP3A4 such as ritonavir. A clinical boost effect was predicted by using physiologically based pharmacokinetic (PBPK) modeling. However, initial boost predictions lacked sufficient confidence because a key parameter, fraction of drug metabolized by CYP3A4 (ƒₘCYP3A4), could not be estimated with accuracy on account of disconnects between in vitro and in vivo preclinical data. To accurately estimate ƒₘCYP3A4 in human, an in vivo boost effect study was conducted using CYP3A4-humanized mouse model which showed a 33- to 56-fold exposure boost effect. Using a top-down approach, human ƒₘCYP3A4 for NVS123 was estimated to be very high and included in the human PBPK modeling to support subsequent clinical study design. The combined use of the in vivo boost study in CYP3A4-humanized mouse model mice along with PBPK modeling accurately predicted the clinical outcome and identified a significant NVS123 exposure boost (∼42-fold increase) with ritonavir.},
  language  = {en}
}
@article{HendersonMclaughlinScheeretal.2015,
  author    = {Henderson, Colin J. and Mclaughlin, Lesley A. and Scheer, Nico and Stanley, Lesley A. and Wolf, C. Roland},
  title     = {Cytochrome b5 Is a Major Determinant of Human Cytochrome P450 CYP2D6 and CYP3A4 Activity In Vivo s},
  series = {Molecular Pharmacology},
  volume    = {87},
  journal   = {Molecular Pharmacology},
  number    = {4},
  publisher = {ASPET},
  address   = {Bethesda},
  issn      = {1521-0111},
  doi       = {10.1124/mol.114.097394},
  pages     = {733 -- 739},
  year      = {2015},
  language  = {en}
}
@article{ScheerKapelyukhRodeetal.2015,
  author    = {Scheer, Nico and Kapelyukh, Yury and Rode, Anja and Oswald, Stefan and Busch, Diana and Mclaughlin, Lesley A. and Lin, De and Henderson, Colin J. and Wolf, C. Roland},
  title     = {Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse Model},
  series = {Drug Metabolism and Disposition},
  volume    = {43},
  journal   = {Drug Metabolism and Disposition},
  number    = {11},
  publisher = {ASPET},
  address   = {Bethesda},
  issn      = {1521-009x},
  doi       = {10.1124/dmd.115.065656},
  pages     = {1679 -- 1690},
  year      = {2015},
  language  = {en}
}